{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'TABLE OF CONTENTS', 'SIGNATURES', '2', 'EMERGENCY CONTACTS', '4', 'SYNOPSIS', '5', 'TABLE OF CONTENTS', '11', '1.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '18', '2.', 'INTRODUCTION', '22', '2.1', 'Background', '22', '2.2', 'Study Treatment', '22', '2.2.1', 'Olokizumab', '22', '2.2.2', 'Nonclinical Development', '24', '2.2.3', 'Summary of Clinical Experience', '25', '2.2.3.1', 'Summary of Studies in the Olokizumab', 'Clinical Program', '25', '2.2.3.2', 'Summary of Safety Data from Olokizumab', 'Studies', '27', '2.2.3.3', 'Summary of Efficacy Data from Olokizumab', 'Studies', '34', '2.2.3.4', 'Summary of Pharmacokinetic Data from', 'Olokizumab Studies', '36', '2.2.4', 'Rationale for Dose Selection', '36', '2.3', 'Rationale for the Study', '37', '2.4', 'Benefit/Risk Assessment', '38', '3.', 'STUDY OBJECTIVES', '40', '3.1', 'Primary Objective', '40', '3.2', 'Secondary Objectives', '40', '4.', 'SUMMARY OF STUDY ENDPOINTS', '41', '4.1', 'Safety Enppoints', '41', '4.2', 'Efficacy Endpoints', '41', '4.3', 'Immunogenicity', '43', '5.', 'INVESTIGATIONAL PLAN', '44', '5.1', 'Summary of Study Design', '44', 'Amendment 2: 06 March 2019', '11', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.2', 'Discussion of Study Design', '50', '5.2.1', 'Cardiovascular Risk Assessment', '51', '5.2.2', 'Safety Follow-up Assessments', '52', '5.3', 'Selection of Study Population', '53', '5.3.1', 'Inclusion Criteria', '53', '5.3.2', 'Exclusion Criteria', '53', '5.3.3', 'Subject Restrictions', '55', '5.3.4', 'Premature Subject Withdrawal', '56', '5.4', 'Study Procedures', '56', '5.4.1', 'Open-label Treatment Period Visits: Visit 1 (OLE', 'Baseline/Week 24) through Visit 9 (Week 88)', '58', '5.4.1.1', 'Visit 1 (OLE Baseline/Week 24)', '58', '5.4.1.2', 'Visit 2 (Week 26)', '60', '5.4.1.3', 'Visit 3 (Week 28)', '61', '5.4.1.4', 'Visit 4 (Week 36)', '62', '5.4.1.5', 'Visit 5 (Week 44)', '64', '5.4.1.6', 'Visit 6 (Week 52)', '65', '5.4.1.7', 'Visit 7 (Week 64)', '66', '5.4.1.8', 'Visit 8 (Week 76)', '67', '5.4.1.9', 'Visit 9 (Week 88)', '69', '5.4.2', 'Visit 10/End of Treatment (2 Weeks After the Last Dose', 'of the Study Treatment)/Week 106)', '70', '5.4.3', 'Safety Follow-Up: Visits SFU-1, SFU-2, and SFU-3', '72', '5.4.3.1', 'Visit SFU-1 (Week 108 or 4 Weeks after the', 'Last Dose of the Study Treatment)', '72', '5.4.3.2', 'Visit SFU-2 (Week 112 or 8 Weeks after the', 'Last Dose of the Study Treatment)', '72', '5.4.3.3', 'Visit SFU-3 (Week 126 or 22 Weeks after the', 'Last Dose of the Study Treatment)', '73', '5.4.4', 'Unscheduled Visit', '73', '5.5', 'Subject Diary', '73', '6.', 'STUDY TREATMENTS', '75', '6.1', 'Study Treatment Administered', '75', '6.2', 'Identity of Study Treatment', '75', '6.2.1 Olokizumab', '75', '6.3', 'Packaging and Labeling', '76', '6.4', 'Storage', '76', '6.5', 'Method of Assigning Subjects to Treatment Group', '77', '6.6', 'Study Treatment Accountability', '77', '6.7', 'Treatment Compliance', '77', '6.8', 'Preparation and Administration of Study Treatment', '78', '6.9', 'Selection and Timing of Dose for Each Subject', '81', '6.10', 'Dose Adjustments', '81', 'Amendment 2: 06 March 2019', '12', 'Confidential']\n\n###\n\n", "completion": "END"}